Srinagar Magazine

DelveInsight’s, “Psoriatic Arthritis Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including Psoriatic Arthritis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Psoriatic Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Psoriatic Arthritis NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Psoriatic Arthritis Pipeline Report

 

• DelveInsight’s psoriatic arthritis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for psoriatic arthritis treatment.

 

• The leading psoriatic arthritis companies such as Sun Pharmaceutical Industries Limited, UCB Biopharma, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Polpharma Biologics, Avotres, XBiotech, Aclaris Therapeutics, Luye Pharma Group, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nimbus Therapeutics, f5 Therapeutics, MoonLake Immunotherapeutics, and others.

 

• Promising psoriatic arthritis pipeline therapies in various stages of development include Tildrakizumab, Bimekizumab, BMS-986165, AbGn-168H, Izokibep, BAT2506, Ustekinumab biosimilar, Apremilast, QX 002N, KPG-612, ALPN 101, AVT001, RHE 70202, ATI-450, Secukinumab biosimilar, DNX 114, SHR 1314, NDI-034858, Research programme: Autoimmune disorder therapeutics, Sonelokimab, and others.

 

• The Psoriatic Arthritis companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The Psoriatic Arthritis pipeline therapies under development are focused on novel approaches to treat/improve Psoriatic Arthritis.

  

To explore more information on the latest breakthroughs in the Psoriatic Arthritis Pipeline treatment landscape of the report, click here @ Psoriatic Arthritis Pipeline Outlook

 

Psoriatic Arthritis Overview

Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies.

 

Recent Developments Activities in the Psoriatic Arthritis Treatment Landscape

 

• In November 2022, BimekizumabDemonstrated Sustained Clinical Responses to Week 52 in Phase III Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis.Data from BE OPTIMAL showed that clinical joint and skin clearance responses in patients with active psoriatic arthritis were sustained to week 52 with bimekizumab treatment.In addition, data from BE MOBILE 1 and BE MOBILE 2 showed that across the full spectrum of axSpA, encompassing nr-axSpA and AS, treatment with bimekizumab resulted in sustained improvement in the signs and symptoms of disease, including suppression of inflammation and improvements in physical function and quality of life, to week 52.

 

• In November 2022, ACELYRIN, INC., announced additional data from a Phase IItrial of izokibep in psoriatic arthritis (PsA) to be presented at the American College of Rheumatology (ACR) Convergence 2022. Izokibep showed consistently high levels of response across multiple disease measures of joint and skin improvement, beginning early and with ongoing improvement. The safety profile of izokibep was generally consistent with other IL-17A inhibitors, and in the trial, event rates were mostly similar to placebo.

 

• In August 2022, The Food and Drug Administration (FDA)expanded the approval of Stelara® (ustekinumab) to include treatment of pediatric patients 6 years of age and older with active psoriatic arthritis (PsA). The approval was supported by evidence from adequate and well-controlled studies of Stelara in adults with psoriasis and PsA, pharmacokinetic (PK) data from adult patients with psoriasis, adult patients with PsA and pediatric patients with psoriasis, and safety data from 2 clinical studies in 44 patients 6 to 11 years old with psoriasis and 110 patients 12 to 17 years old with psoriasis.

 

• In May 2022, ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd. announced that a 16-week, global, Phase II clinical trial of izokibepin 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50. Izokibep also achieved secondary endpoints, including PASI response, enthesitis LEEDs improvement, and quality of life improvement on a clinically validated PsA-specific quality of life instrument, the Psoriatic Impact of Disease (PsAID) questionnaire.

 

• In January 2022, AbbVie announced the U.S. Food and Drug Administration(FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.The FDA approval was supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy and safety of SKYRIZI in adults with active PsA, including those who had responded inadequately or were intolerant to biologic therapy and non-biologic disease-modifying antirheumatic drugs (DMARDs).

 

For further information, refer to the detailed Psoriatic Arthritis Unmet Needs, Psoriatic Arthritis Market Drivers, and Psoriatic Arthritis Market Barriers, click here for Psoriatic Arthritis Ongoing Clinical Trial Analysis

 

Psoriatic Arthritis Emerging Drugs Profile

 

• ABT-494: AbbVie

Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. In August 2019, RINVOQ received U.S. Food and Drug Administration approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ also received approval by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Phase 3 trials of RINVOQ in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.

 

• Risankizumab: Abbvie

Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis.

 

Psoriatic Arthritis Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Psoriatic Arthritis. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Registered include, Abbvie.

 

Request a sample and discover the recent advances in Psoriatic Arthritis Ongoing Clinical Trial Analysis and Medications, click here @ Psoriatic Arthritis Treatment Landscape

 

Scope of the Psoriatic Arthritis Pipeline Insight Report

 

• Coverage- Global

 

• Psoriatic Arthritis Companies– Sun Pharmaceutical Industries Limited, UCB Biopharma, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Polpharma Biologics, Avotres, XBiotech, Aclaris Therapeutics, Luye Pharma Group, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nimbus Therapeutics, f5 Therapeutics, MoonLake Immunotherapeutics, and others.

 

• Psoriatic Arthritis Pipeline Therapies- Tildrakizumab, Bimekizumab, BMS-986165, AbGn-168H, Izokibep, BAT2506, Ustekinumab biosimilar, Apremilast, QX 002N, KPG-612, ALPN 101, AVT001, RHE 70202, ATI-450, Secukinumab biosimilar, DNX 114, SHR 1314, NDI-034858, Research programme: Autoimmune disorder therapeutics, Sonelokimab, and others.

 

• Psoriatic Arthritis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Psoriatic Arthritis Market Drivers and Psoriatic Arthritis Market Barriers, click here @ Psoriatic Arthritis Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Psoriatic Arthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriatic Arthritis– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Psoriatic Arthritis Collaboration Deals
9. Late Stage Products (Registered/Launch)
10. MYL-1401A: Mylan
11. Drug profiles in the detailed report…..
12. Late Stage Products (Registered)
13. ABT-494: AbbVie
14. Drug profiles in the detailed report…..
15. Late Stage Products (Preregistration)
16. Tildrakizumab: Sun Pharma Global
17. Drug profiles in the detailed report…..
18. Late Stage Products (Phase III)
19. Filgotinib: Gilead Sciences
20. Drug profiles in the detailed report…..
21. Mid Stage Products (Phase II)
22. PF-06700841: Pfizer
23. Drug profiles in the detailed report…..
24. Early Stage Products (Phase I)
25. BAT2506: Bio-Thera Solutions
26. Drug profiles in the detailed report…..
27. IND Stage Products
28. KPG-612: Kangpu Biopharmaceuticals
29. Drug profiles in the detailed report…..
30. Preclinical Stage Products
31. ALPN 101: Alpine Immune Sciences
32. Drug profiles in the detailed report…..
33. Discovery Stage Products
34. DNX 514: DNX Biopharmaceuticals
35. Inactive Products
36. Psoriatic Arthritis Key Companies
37. Psoriatic Arthritis Key Products
38. Psoriatic Arthritis- Unmet Needs
39. Psoriatic Arthritis- Market Drivers and Barriers
40. Psoriatic Arthritis- Future Perspectives and Conclusion
41. Psoriatic Arthritis Analyst Views
42. Psoriatic Arthritis Key Companies
43. Appendix

 

Got Queries? Find out the related information on Psoriatic Arthritis Mergers and acquisitions, Psoriatic Arthritis Licensing Activities @ Psoriatic Arthritis Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/